PA
CYT

Parallel Advisors’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Parallel Advisors’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-464
Closed -$1K – 3563
2022
Q3 		$1K Hold
464
– – ﹤0.01% 3074
2022
Q2 		$1K Buy
+464
New +$1.19K ﹤0.01% 2911

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors's CYT Position: Q4 2022 in Review

Parallel Advisors sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2022, closing a stake of 464 shares — an estimated $1K sold.

Parallel Advisors first reported a position in CYT in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 30 funds tracked by Wall St. Rank hold CYT as of Q4 2022.

  • Parallel Advisors reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 464 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • Parallel Advisors first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Parallel Advisors's Cyteir Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.